The worldwide weight-loss revolution
<p>GLP-1 weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are reshaping the treatment of obesity around the world. But even when these medicines are judged “cost-effective”, access often depends on who can afford to pay. In the second episode of our Business Daily series on the global weight-loss economy, Sam Fenwick examines how different countries are funding — or rationing — access to these high-priced injections. In England, the state's National Health System says the drugs offer good value …
Tsy mbola voasoratra io fizarana io
Ampiasao ny STT.ai hanoratana ity fizarana ity amin'ny AI. Azonao atao ny mahazo lahatsoratra marina miaraka amin'ny famantarana ny mpiteny, ny famantarana ny fotoana, ary ny fanondranana amin'ny lamina maro.